$1.323.65%-0.05

Femasys Inc (FEMY)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relatives Volumen:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1Y Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Femasys Inc Aktie (FEMY) Unternehmensprofil

770-500-3910

3950 JOHNS CREEK COURT, SUWANEE, USA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

FEMY-Diskussionen auf X

Femasys Inc Aktie (FEMY) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2025-11-20	Eingeleitet	Laidlaw	Buy

Finanzdaten der Femasys Inc-Aktie (FEMY)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	2.29	1.63	1.07	1.21	1.18
Cost of revenue USD (M)	0.87	0.54	0.38	0.44	0.37
Gross profit USD (M)	-	-	0.69	0.76	0.81
Research and development USD (M)	7.58	8.22	7.21	5.81	4.08
Operating expenses USD (M)	19.01	18.87	15.20	12.36	9.15
Operating income USD (M)	-17.59	-17.79	-14.51	-11.60	-8.34
Income before tax USD (M)	-18.63	-18.81	-14.24	-11.39	-7.53
Income tax expense USD (M)	0.00	0.01	0.00	0.01	0.00
Net income USD (M)	-18.63	-18.82	-14.25	-11.39	-7.54
Basic EPS USD/shares	-0.47	-0.85	-0.93	-0.96	-1.12
Diluted EPS USD/shares	-0.47	-0.85	-0.93	-0.96	-1.12
Basic weighted shares shares (M)	39.55	22.27	15.38	11.82	6.71
Diluted weighted shares shares (M)	39.55	22.27	15.38	11.82	6.71

Femasys Inc-Aktie (FEMY) Insiderhandel

Mifek Jeffrey GeraldAug 07 '26
Chief Clinical-Medical Affairs
Transaktion
Buy
Kosten
$3.20
#Aktien
3,125
Wert ($)
10,000
#Aktien Gesamt
3,125
Sipos Jeremy AlexanderAug 07 '26
Chief Technology Officer
Transaktion
Buy
Kosten
$3.20
#Aktien
3,125
Wert ($)
10,000
#Aktien Gesamt
3,125
Canning John CharlesAug 07 '26
Chief Operating Officer
Transaktion
Buy
Kosten
$3.20
#Aktien
4,375
Wert ($)
14,000
#Aktien Gesamt
4,375
Elefant DovAug 07 '26
Chief Financial Officer
Transaktion
Buy
Kosten
$3.20
#Aktien
15,625
Wert ($)
50,000
#Aktien Gesamt
15,625
Lee-Sepsick KathyAug 07 '26
Chief Executive Officer
Transaktion
Buy
Kosten
$3.20
#Aktien
15,625
Wert ($)
50,000
#Aktien Gesamt
15,625

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Mifek Jeffrey Gerald	Chief Clinical-Medical Affairs	Aug 07 '26	Buy	$3.20	3,125	10,000	3,125
Sipos Jeremy Alexander	Chief Technology Officer	Aug 07 '26	Buy	$3.20	3,125	10,000	3,125
Canning John Charles	Chief Operating Officer	Aug 07 '26	Buy	$3.20	4,375	14,000	4,375
Elefant Dov	Chief Financial Officer	Aug 07 '26	Buy	$3.20	15,625	50,000	15,625
Lee-Sepsick Kathy	Chief Executive Officer	Aug 07 '26	Buy	$3.20	15,625	50,000	15,625

Femasys Inc Aktie (FEMY) Neueste Nachrichten

Femasys Inc (FEMY)

Femasys Inc Aktie (FEMY) Unternehmensprofil

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Femasys Inc Aktie (FEMY) Hochstufungen & Herabstufungen

Finanzdaten der Femasys Inc-Aktie (FEMY)

Femasys Inc-Aktie (FEMY) Insiderhandel

Femasys Inc Aktie (FEMY) Neueste Nachrichten

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs - GlobeNewswire Inc.

Empery Asset Management Reports 5.6% Ownership Stake in Femasys Inc. - Kalkine Media

A fund manager reports a passive 468,750-share stake in Femasys (FEMY). - Stock Titan

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control - GlobeNewswire Inc.

Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com Nigeria

Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com UK

Femasys Inc (NASDAQ: FEMY) Share Price, FEMY Stock News, FEMY Share Price & Updates - Kalkine

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance

Femasys Company Profile & Introduction - Moomoo

Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus

Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing - TradingView

Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan

Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan

Femasys (FEMY) Stock News & Analysis - TechStock²

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com Canada

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com UK

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times

Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the Day - Value Stock Ideas - vinanet.vn

Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the Day - Composite Profile - dars.gov.et

Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest Reading - Volume Dry Up - vinanet.vn

Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest Reading - Hagopian Line - siam.in

Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest Trading - Volatility Smirk - vinanet.vn

Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan

Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm

Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com

Why Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY) - Benzinga

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView

Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria

Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current Session - Low Growth Earnings - Vinanet

Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance

Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com

FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan

Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com India

Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record

Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - marketscreener.com

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Yahoo Finance

Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current Session - Analyst Coverage Count - dars.gov.et

Femasys secures $30 million to advance fertility portfolio - The Pharma Letter

Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan

FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31% - Earnings Turnaround - vinanet.vn

Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us

Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade

Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan

Ähnlich wie FEMY